Compare KeyCorp (KEY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Mesoblast Limited — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: KeyCorp is far larger — about 12.3× Mesoblast Limited's market cap, and KeyCorp pays a 4.08% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Mesoblast Limited for 15 Days on average.
| KEY | MESO | |
|---|---|---|
Market Cap | $21.45B | $1.75B |
Volume | 19,450,846 | 239,027 |
Sector | Financials | Health |
52-Week High | $23.99 | $20.96 |
52-Week Low | $16.78 | $13.19 |
Typical Hold Time | 66 Days | 15 Days |
Enterprise Value | $34.63B | $1.83B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.97, up 0.71% with strong recent earnings beats and a 60.79% analyst buy rating. The stock shows bearish technical signals but maintains solid fundamentals with 26.72% net margin and 11.01% ROE. Recent corporate actions include a $0.21 dividend and executive appointments, while cash flow trends show operational stability despite recent net outflows.
KEY presents a compelling value opportunity with 25% upside to consensus target, supported by earnings momentum and dividend stability. Risks include technical bearish pressure, interest rate sensitivity, and competitive dividend landscape. The bank's improved 2026 revenue guidance and institutional accumulation suggest underlying strength despite near-term headwinds.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
